EGFR Tyrosine Kinase Inhibitors Serine-Threonine Kinase Inhibitors Threonine-Tyrosine Kinase Inhibitors Chemotherapy DNA BCL Inhibitors Cyclin Dependent Kinase Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy | Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Rectal Cancer | Colon Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Pancreatic Cancer | Acute Myelogenous Leukemia | Glioblastoma | Biliary Tract Cancer | Ovarian Serous Adenocarcinoma |
---|---|---|---|---|---|---|---|---|---|---|---|
panitumumab | |||||||||||
cetuximab | |||||||||||
5-fluorouracil + oxaliplatin | |||||||||||
VS-6766 + VS-6063 | |||||||||||
gemcitabine + albumin-bound paclitaxel | |||||||||||
venetoclax | |||||||||||
SCT200 | |||||||||||
cetuximab + palbociclib | |||||||||||
bevacizumab | |||||||||||
CPGJ-602 | |||||||||||
panitumumab + cabozantinib tablet | |||||||||||
SIRB | |||||||||||
durvalumab + tremelimumab | |||||||||||
nivolumab | |||||||||||
EGFR inhibitor | |||||||||||
VEGF inhibitor | |||||||||||
nimotuzumab | |||||||||||
MM-121 | |||||||||||
VS-6766 + VS-4718 | |||||||||||
VS-4718 |